ethyl β-monofluoromethylacrylate | 371-24-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl β-monofluoromethylacrylate
• 英文别名: ethyl 4-fluorobut-2-enoate；Ethyl-4-fluorocrotonat
• CAS: 371-24-4
• 化学式: C₆H₉FO₂
• 分子量: 132.135
• InChiKey: FUQNDTQEJQPNFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl β-monofluoromethylacrylate 在 sodium hydroxide 作用下， 生成 (E)-4-fluorobut-2-enoic acid
  参考文献：
  名称：

  Stereochemistry of the Diels-Alder reaction. V. Fluorinated trans-olefinic acids and derivatives with cyclopentadiene

  摘要：

  DOI：

  10.1021/jo00944a002
• 作为产物：
  描述：

  4-氯-4-氟-3-氧代丁酸乙酯 在 sodium tetrahydroborate 、 偶氮二异丁腈 、 三正丁基氢锡 、 三乙胺 、 对甲苯磺酰氯 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 27.5h， 生成 ethyl β-monofluoromethylacrylate
  参考文献：
  名称：

  Diels-Alder方法对氟甲基化的立体碳中心进行对映选择性构建。

  摘要：

  β-氟甲基丙烯酸酯的高度对映选择性Diels-Alder反应在路易斯酸活化的手性恶唑硼烷催化剂的存在下进行。这些反应产生了氟甲基化的环己烯，包括三氟甲基-，二氟甲基-和一氟甲基环己烯，为几乎纯的对映异构体。将所得的氟甲基环己烯转化为生物活性化合物的潜在合成中间体。

  DOI：

  10.1039/c1cc15889a

文献信息

• Solid dispersions containing an apoptosis-inducing agent
  申请人：AbbVie Inc.

  公开号：US10213433B2

  公开（公告）日：2019-02-26

  A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

  一种促凋亡的固体分散体包括本文所定义的具有本文所述的化学式I的Bcl-2家族蛋白抑制化合物，以基本非晶态形式分散在包括（a）药学上可接受的水溶性聚合物载体和（b）药学上可接受的表面活性剂的固体基质中。制备这种固体分散体的方法包括在合适的溶剂中溶解化合物、聚合物载体和表面活性剂，并去除溶剂以提供包括聚合物载体和表面活性剂并在其中以基本非晶态形式分散有化合物的固体基质。这种固体分散体适用于口服给予需要治疗由一个或多个抗凋亡Bcl-2家族蛋白过度表达所特征的疾病的受试者，例如癌症。
• Novel enzyme inhibitors
  申请人：Richardson-Merrell Inc.

  公开号：US04277395A1

  公开（公告）日：1981-07-07

  Compounds of the following general formula are irreversible inhibitors of pancreatic elastase: ##STR1## wherein M is hydroxy, lower alkoxy, benzyloxy or --NY.sub.1 Y.sub.2 wherein each of R.sub.4 and R.sub.5 is hydrogen or lower alkyl; R is CF.sub.3, CHF.sub.2 or CH.sub.2 F; R.sub.1 is straight or branched lower alkyl; R.sub.2 is defined the same as R.sub.1 or is benzyl; R.sub.30 is CHO, carbobenzoxy, tert-butoxycarbonyl, benzoyl or lower alkanoyl; X is pro, ala or leu and Y and Z together form a single bond; or Y-X is ala-pro, ala-ala or ala-leu and Z forms a single bond; and Z-Y-X is ala-ala-pro, ala-ala-ala or pro-ala-leu.

  以下通式的化合物是胰弹性蛋白酶的不可逆抑制剂：##STR1## 其中M为羟基，低烷氧基，苄氧基或--NY.sub.1 Y.sub.2，其中R.sub.4和R.sub.5中的每一个都是氢或低烷基；R为CF.sub.3，CHF.sub.2或CH.sub.2 F；R.sub.1为直链或支链低烷基；R.sub.2与R.sub.1的定义相同或为苯甲基；R.sub.30为CHO，羧苄氧基，叔丁氧羰基，苯甲酰基或低烷酰基；X为丙氨酸，丙氨酰基或亮氨酸，Y和Z共同形成单键；或者Y-X为丙氨酰基-丙氨酸基，丙氨酰基-丙氨酰基或丙氨酰基-亮氨酸基，Z形成单键；并且Z-Y-X为丙氨酰基-丙氨酰基-丙氨酰基，丙氨酰基-丙氨酰基-丙氨酰基或丙氨酰基-丙氨酰基-亮氨酸基。
• SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
  申请人：Catron Nathaniel

  公开号：US20120277210A1

  公开（公告）日：2012-11-01

  A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

  一种促凋亡固体分散体包括本文所定义的公式I的Bcl-2家族蛋白抑制化合物，以基本非晶态形式分散在包含（a）药用可接受的水溶性聚合物载体和（b）药用可接受的表面活性剂的固体基质中。制备这种固体分散体的过程包括在适宜的溶剂中溶解化合物、聚合物载体和表面活性剂，并去除溶剂以提供包含聚合物载体和表面活性剂的固体基质，并在其中分散具有基本非晶态形式的化合物。该固体分散体适用于口服给予需要治疗由一个或多个抗凋亡Bcl-2家族蛋白过度表达的疾病的患者，例如癌症。
• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：Bruncko Milan

  公开号：US20120190688A1

  公开（公告）日：2012-07-26

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  本发明涉及一种抑制抗凋亡Bcl-2蛋白活性的化合物，以及含有该化合物的组合物和治疗表达抗凋亡Bcl-2蛋白相关疾病的方法。
• MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
  申请人：Birtalan Esther

  公开号：US20120108590A1

  公开（公告）日：2012-05-03

  A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.

  一种促凋亡的固体分散体，其中本质上非结晶形式地分散着一种Bcl-2家族蛋白抑制化合物，该化合物的化学式如本文所定义，该固体分散体分散在包含（a）药用可接受的水溶性聚合物载体和（b）药用可接受的表面活性剂的固体基质中。制备这种固体分散体的过程包括将化合物I的水溶性聚合物载体和表面活性剂加热至高温，以提供可挤出的半固体混合物；挤出半固体混合物；并冷却所得的挤出物，以提供包含聚合物载体和表面活性剂的固体基质，并在其中分散化合物的本质上非结晶形式。该固体分散体适用于口服给予需要治疗由一个或多个抗凋亡Bcl-2家族蛋白过度表达所特征的疾病的患者，例如癌症或免疫或自身免疫疾病。